Use of Rituximab in the Management of Sjögren’s Syndrome

Carubbi, Francesco; Alunno, Alessia; Cipriani, Paola; Berardicurti, Onorina; Ruscitti, Piero; Liakouli, Vasiliki; Ciccia, Francesco; Triolo, Giovanni; Gerli, Roberto; Giacomelli, Roberto

doi:10.1007/s40674-015-0025-4

Cited by 3 publications

(1 citation statement)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CD20 Targeting CD20 antigen, which was found on immature-B and mature B cells, was used as a target for B cell depletion therapy (Figure 5) [210]. Rituximab, a humanized anti-CD20 monoclonal antibody was used in several open-label studies to treat primary SS [211]. Binding of rituximab to CD20-expressing B cells leads to antibody-dependent cellular cytotoxicity, complement-mediated cytotoxicity, and apoptosis-mediated transient B cell depletion in peripheral blood, salivary glands, and other target tissues [212].…”

Section: B Cell Targetingmentioning

confidence: 99%

Innate Immunity and Biological Therapies for the Treatment of Sjögren’s Syndrome

Srivastava

Makarenkova

2020

IJMS

View full text Add to dashboard Cite

Sjögren’s syndrome (SS) is a systemic autoimmune disorder affecting approximately 3% of the population in the United States. This disease has a female predilection and affects exocrine glands, including lacrimal and salivary glands. Dry eyes and dry mouths are the most common symptoms due to the loss of salivary and lacrimal gland function. Symptoms become more severe in secondary SS, where SS is present along with other autoimmune diseases like systemic lupus erythematosus, systemic sclerosis, or rheumatoid arthritis. It is known that aberrant activation of immune cells plays an important role in disease progression, however, the mechanism for these pathological changes in the immune system remains largely unknown. This review highlights the role of different immune cells in disease development, therapeutic treatments, and future strategies that are available to target various immune cells to cure the disease.

show abstract

Section: B Cell Targetingmentioning

confidence: 99%